MoonLake Immunotherapeutics MLTX Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's short- and long-term operating lease liabilities?
- MoonLake Immunotherapeutics (MLTX) reported short- and long-term operating lease liabilities of -$389K in Q1 2026.
- How has MoonLake Immunotherapeutics's short- and long-term operating lease liabilities changed year-over-year?
- MoonLake Immunotherapeutics's short- and long-term operating lease liabilities decreased by 52.5% year-over-year, from -$255K to -$389K.
- What is the long-term trend for MoonLake Immunotherapeutics's short- and long-term operating lease liabilities?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's short- and long-term operating lease liabilities has grown at a 100.1% compound annual growth rate (CAGR), from -$152.43K to -$1.22M.